Rallybio Corp Operating Income Over Time
| RLYB Stock | USD 10.55 0.04 0.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Rallybio Corp Performance and Rallybio Corp Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rallybio Corp. Anticipated expansion of Rallybio directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Rallybio Corp assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.56) | Revenue Per Share | Quarterly Revenue Growth (0.29) | Return On Assets | Return On Equity |
The market value of Rallybio Corp is measured differently than its book value, which is the value of Rallybio that is recorded on the company's balance sheet. Investors also form their own opinion of Rallybio Corp's value that differs from its market value or its book value, called intrinsic value, which is Rallybio Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rallybio Corp's market value can be influenced by many factors that don't directly affect Rallybio Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Rallybio Corp's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rallybio Corp should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Rallybio Corp's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Rallybio Corp and related stocks such as Intensity Therapeutics, Sonnet Biotherapeutics, and Iterum Therapeutics PLC Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INTS | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (6.2 M) | (8 M) | (7.5 M) | (8.3 M) | (16.6 M) | (14.9 M) | (14.2 M) |
| ITRM | (13.4 M) | (13.4 M) | (13.4 M) | (13.4 M) | (13.4 M) | (13.4 M) | (13.4 M) | (29.5 M) | (76.6 M) | (102 M) | (32.1 M) | (24.5 M) | (30.4 M) | (47.5 M) | (18.7 M) | (21.5 M) | (22.6 M) |
| TAOX | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (16.1 M) | (8.3 M) | (6.8 M) | (7.8 M) | (8.2 M) |
| IBIO | (1.7 M) | (9.3 M) | (6.7 M) | (3.8 M) | (6.7 M) | (9.9 M) | (14.3 M) | (14.2 M) | (15.8 M) | (14 M) | (31.1 M) | (29.7 M) | (29.3 M) | (16.6 M) | (18.6 M) | (16.7 M) | (17.6 M) |
| KLTO | (913.1 K) | (913.1 K) | (913.1 K) | (913.1 K) | (913.1 K) | (913.1 K) | (913.1 K) | (913.1 K) | (913.1 K) | (913.1 K) | (913.1 K) | (1.1 M) | (574.4 K) | (631.3 K) | (5.5 M) | (5 M) | (4.7 M) |
| CVKD | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (7.6 M) | (11 M) | (9.9 M) | (10.4 M) |
| XCUR | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (16.2 M) | (10.4 M) | (21.8 M) | (26.6 M) | (25.4 M) | (62.5 M) | (1.8 M) | (15 M) | (12.2 M) | (11 M) | (11.6 M) |
| BOLD | (60 M) | (60 M) | (60 M) | (60 M) | (60 M) | (60 M) | (60 M) | (93.2 M) | (134.4 M) | (25.3 M) | (25.3 M) | (25.3 M) | (46.5 M) | (54.8 M) | (73.3 M) | (84.3 M) | (88.5 M) |
| QTTB | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (29.7 M) | (59.9 M) | (109.9 M) | (130.3 M) | (95.9 M) | (39.2 M) | (48.3 M) | (66.1 M) | (59.5 M) | (62.5 M) |
Rallybio Corp and related stocks such as Intensity Therapeutics, Sonnet Biotherapeutics, and Iterum Therapeutics PLC Operating Income description
Operating Income is the amount of profit realized from Rallybio Corp operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Rallybio Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Rallybio Corp | RLYB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 234 Church Street, |
| Exchange | NASDAQ Exchange |
USD 10.55
Check out Rallybio Corp Performance and Rallybio Corp Correlation. For information on how to trade Rallybio Stock refer to our How to Trade Rallybio Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Rallybio Corp technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.